Most health-care providers and patients will agree that drugs do not aff ect everyone in the same way. Th e eff ect that a drug may have on an individual may vary with respect to clinical effi cacy (the intended response) or experience of side or adverse eff ects (an unintended response). Th is variability in treatment eff ect at times can be explained by diff erences in dosing, administration (e.g., taken on an empty stomach or aft er eating), or physiology or metabolism (e.g., weight). Many times, in the absence of these factors being accounted for, there is increasing recognition that there may be a genetic basis for diff erences in drug eff ects. As the costs of sequencing DNA continue to decrease and awareness of the role of genetics in predicting drug response increases, the number of clinical applications for genetic testing in gastrointestinal (GI) disease is bound to increase in the near future.
Th e terms " pharmacogenetics " and " pharmacogenomics " are frequently used interchangeably, but a distinction between the two terms exists. Pharmacogenetics is the fi eld of study that examines the relationship between individual genetic variants and drug eff ects. In contrast, pharmacogenomics is the fi eld of study that examines the relationship between a number or collection of genetic variants and drug eff ects. At present, the scale of our current understanding of genetic eff ects on drug eff ects is still generally at the single gene level, but great promise lies in elucidating the roles of genetic combinations and their eff ects. To explain the current status of pharmacogenetics and its future in GI disease, this brief review will provide an overview of genetic terms and concepts, pharmacogenetic terms and concepts, examples of known genetic variants that aff ect treatment response in GI disease, and will conclude with the future directions and challenges that exist in this fi eld.
GENOMICS AND GENETICS PRINCIPLES
Before discussing known genes and their variants that are known to aff ect human pharmacokinetics and pharmacodynamics, a brief overview of genetics follows to provide a contextual background. Th e human genome is the entire collection of DNA in a human being. Although in other organisms genetic information can be provided by RNA as well (e.g., viruses), DNA is the genetic template for humans. Th e human genome consists of 46 chromosomes -44 autosomal chromosomes and 2 sexlinked chromosomes. Within these chromosomes, there are ~ 3 billion base pairs with an estimated 30,000 coding genes in the genome. Within each gene, several coding exons and noncoding introns exist. Th e size of a gene is usually determined by the intron length, and the range of gene sizes is 1 -100 kb, with the average human gene being 27 kb in length.
Th roughout the genome and between individuals, there are thousands of genetic variations. Th e genetic variants are also referred to as polymorphisms, if the minor allele frequency is present in more than 1 % of the general population. Th ese polymorphisms are referred to as " mutations " if rare (present in < 1 % of the general population). Th ese polymorphisms may be functional (resulting in a measurable change in How are these genetic diff erences detected on an individual basis? Traditionally, methods for sequencing DNA were quite labor intensive requiring direct sequencing by cleaving DNA base pair by base pair. However, the most cost-and time-effi cient methods for genotyping polymorphisms relevant in pharmacogenetics typically are PCR-based modalities that require the selection of a sense and anti-sense primer, which fl anks the polymorphism of interest. Furthermore, with the creation of high-throughput modalities, sequencing of thousands of genetic markers spanning the genome or a segment of the genome is now feasible in a matter of days and weeks rather than years. Th ese signifi cant advances in sequencing technologies have made genotyping of a single gene to a thousand genes more time effi cient, and therefore, cost effi cient. Th e lower genotyping costs provide the future promise that pharmacogenetic genotyping and therefore, individualized treatment selection will be available for all patients.
PHARMACOGENETICS: THE LINK BETWEEN GENETICS AND DRUG RESPONSE
In contrast to genetics, which focuses on disease development and susceptibility, pharmacogenetics focuses on the link between genes and drug response. By defi nition, only functional genetic variants are of interest in pharmacogenetics. However, these functional genetic variations or alterations need not lie in the coding exons to be functional, but may also lie in the non-coding, regulatory regions of the genome. Genes that encode proteins that function as transporters responsible for drug absorption and metabolism, drug receptors, or enzymes, in the metabolic and catabolic pathways are of the greatest relevance in pharmacogenetics. Th ese genetic alterations have the potential to aff ect drug pharmacodynamics (the relationship between drug concentrations and eff ect) or pharmacokinetics (the relationship between drug dose and drug concentrations). Factors related to pharmacodynamics -which focus on drug eff ects -tend to be disease specifi c, whereas those related to pharmacokinetics -which focus on drug concentrations -are more generalizable across drugs and diseases.
Identifi cation of the relevant polymorphisms that aff ect drug response is not necessarily an easy task, as many proteins may be involved in the traffi cking and processing of drugs, and the number of polymorphisms in the genome is high. Not counting VNTRs or RFLPs, there are approximately 8 -10 million SNPs in the human genome with ~ 1 SNP every 1,000 base pairs. Th us, if the average gene is 27 kb, there will be ~ 27 SNPs per gene. Elucidating which SNPs are functional and which are not requires a combination of clinical and laboratory work to determine the physiological consequence and clinical relevance of each polymorphism.
PHARMACOGENETIC APPLICATIONS IN GI DISEASES
Th is fi eld promises clinicians and patients the future ability to allow individualized, patient-specifi c selection of drugs and drug dosing, which maximizes treatment response and minimizes adverse eff ects. However, at present, within the fi eld of gastroenterology and hepatology, pharmacogenetics currently only has one established clinical application, that of thiopurine-S -methyltransferase (TPMT) genetic testing for azathioprine and 6-mercaptopurine (6-MP) dosing in infl ammatory bowel disease. In addition to TPMT testing, there are a number of known genetic polymorphisms linked to drug response that have yet to reach prime time. A summary of GI diseases, drugs, genes, protein products, clinical eff ects, and alleles is outlined in Table 1 .
PRESENT DAY PHARMACOGENETICS: TPMT TESTING IN INFLAMMATORY BOWEL DISEASE
As the only clinically used test at present, TPMT testing in infl ammatory bowel disease is a good example of how clinical decision making can be guided by genetic testing. Azathioprine and 6-MP are related immunomodulating agents used in corticosteroid-dependent patients with either ulcerative colitis or Crohn ' s disease. Azathioprine is a pro-drug that becomes 6-MP non-enzymatically. 6-MP can then be converted into 6-methyl-mercaptopurine by TPMT, into 6-thiouric acid by xanthine oxidase, or into 6-thioguanine nucleotides by other enzymes. Th e enzymatic activity level of TPMT is one factor that determines how quickly 6-MP is broken down, and thus how long 6-MP is present and available in the body, and the type and quantity of metabolites present aft er administration. Specifi cally, low TPMT activity results in increased production of cytotoxic thioguanines.
Th e TPMT gene is 34 kb long and contains 10 exons. Th is gene is located on chromosome 6 at location 6p22.3 ( Figure 1 ). More than 20 mutant alleles have been reported to be responsible for TPMT activity defi ciency. Th e genotype of an REVIEW Pharmacogenetics and Genomics quences. Th is tends to occur when a genetic variant has a " strong " eff ect. However, many genetic variants exist in the genome, and many will likely have weaker genetic eff ects with less clear clinical implications. For example, a specifi c genetic variant may be associated with a " 30 % increased risk of pancreatitis, " but in the right clinical setting, may not preclude a health-care provider from prescribing such a medication if the potential benefi ts are high. Furthermore, racial diff erences in genotype and allele frequencies are common, and thus, the interpretation of genetic data will need to be implemented in a race-conscious manner. Some patients have relatively homogeneous ethnicities but many do not, and greater knowledge and understanding of the race-specifi c genotype frequencies may be useful to the ordering clinician. In addition, gene -environment interactions may also be the rule rather than the exception, and interpretation of some genetic data may not be feasible without a clear understanding of the environmental contributors to disease and response to therapy.
THE FUTURE PROMISE OF PHARMACOGENETICS
Th e combination of genetics and pharmacology is exciting with respect to maximizing treatment outcomes and / or minimizing adverse treatment eff ects. At present, the promise of the fi eld is great but has yet to anywhere reach its full potential. Although the sequence of the human genome is known, the clinical signifi cance of each variation in the DNA code is not yet known, let alone the eff ect of a combination of variations. Much of these limitations will be overcome as sequencing technologies facilitate the ease of genotyping, bringing down the cost of genotyping further and allowing for greater research into the fi eld. Th e current status of the fi eld is evaluating a single polymorphism in a single gene for a handful of diseases. However, the greater promise lies in evaluating multiple polymorphisms in multiple genes -potentially those that lie in the same drug metabolic pathway -spanning the entire genome. Th us, in the not-so-distant future, genotyping 20 -30 functional SNPs in several genes may allow for greater accuracy in recommending specifi c drug dosing for patients.
In the more distant future, pharmacogenetics will likely go beyond genotyping 20 -30 functional SNPs in an individual to genotyping 100 -300,000 select SNPs using high-throughput genotyping technologies, which are currently available (albeit these platforms are still relatively expensive) by analyzing haplotypes, which are alleles that tend to be inherited together because their link has not been disrupted by recombination. Th e advantage that haplotypes off er is that they allow the genotyping of one allele in a haplotype as a proxy marker for the other alleles in the haplotype, thus decreasing the need to genotype all polymorphisms in the haplotype. Th e HapMap Project is a multi-country, collaborative eff ort to catalog the SNP genetic variants and their haplotype combinations of four populations with African, Asian, and European ancestry ( http://www.hapmap.org ). Th e project is identifying " tag " SNPs that uniquely individual determines side eff ects from immunomodulators. An individual who is homozygous wild type will have high TPMT activity, whereas an individual who is heterozygous will have intermediate TPMT activity, and an individual who is homozygous variant will have low TPMT activity. Th ose with low TPMT activity are at the greatest risk for myelosuppression. As such, the FDA (Food and Drug Administration) recommends that the TPMT genotype should be evaluated before administration of azathioprine or 6-MP. Th ose with low TPMT activity levels should not receive these agents. Th ose who are homozygous wild type should receive an initial dose of 2 -2.5 mg / kg of azathioprine or 1 -1.5 mg / kg of 6-MP but should still have their blood counts monitored. Th ose with intermediate activity should receive an attenuated initial dose of 1 -1.5 mg / kg of azathioprine or 0.75 mg / kg of 6-MP (2,3) . In summary, TPMT genetic testing is a successful example of how pharmacogenetics can positively aff ect disease management outcome in a GI disease.
NEAR-FUTURE PHARMACOGENETICS: AMPLICHIP CYP450
Proton pump inhibitors (PPIs) are used frequently to treat acid refl ux, peptic ulcers, and functional dyspepsia, and are used in combination with antibiotics to treat Helicobacter pylori infections. In contrast to drugs, such as azathioprine or 6-MP, which have signifi cant adverse event profi les, less thought regarding dosing has generally been given to the generally safe PPIs. Nonetheless, the pharmacokinetics of this drug class is infl uenced by genetics, and may have relevance in assisting health-care providers in selecting the optimal dose for their specifi c patients. Cytochrome P450, subfamily IIC, polypeptide 19 (CYP2C19) in the liver is the main enzyme responsible for PPI drug elimination (4) . Various alleles ( Table 1 ) have been reported with a gene-dose eff ect that infl uences rates of healing for endoscopically-proven esophagitis as well as rates of H. pylori eradication. For example, cure rates were 73, 69, and 57 % at 4 weeks for poor metabolizers, heterozygotes, and extensive (wild-type) metabolizers, and 100, 95, and 77 % at 8 weeks in Japan (5) . Similarly, the extensive, wild-type metabolizers showed 20 % lower cure rates in the treatment of H. pylori (6) . More recently, a microarray-based AmpliChip CYP450 test was made commercially available by Roche (Nutley, NJ). Because of the ease of testing, this test may become incorporated in routine practice, particularly in Asia where these genetic variants are common. However, the cost eff ectiveness of such testing still remains to be determined, and additional validation of the clinical yield for this chip is merited before incorporation in standard clinical practice.
LIMITATIONS AND CHALLENGES OF PHARMACOGENOMIC DATA
Ideally, genetic variants would allow for a clear interpretation of its results with actionable clinical implications or conse-
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Saito and Talley identify these haplotypes, with an estimated 300 -600,000 tag SNPs to be identifi ed. Th is fi gure is much smaller than the estimated 10 million SNPs that one would need to genotype across the genome. Th us, it is conceivable that patients will be carrying medical information " chips " with their haplotype data to allow optimal selection of drug dosing for any drug with a pharmacogenetic basis.
CONCLUSIONS
Although there has been much hype about pharmacogenetics in medical circles and in the general public promising " individualized medicine, " pharmacogenetics at present has limited applications, particularly in the fi eld of clinical gastroenterology. Furthermore, pharmacogenomics -the fi eld that evaluates multiple genetic eff ects on drug responseoff ers great promise in the future, but at present, has sparse concrete applications in gastroenterology. Nonetheless, TPMT gene testing for azathioprine and 6-MP dosing in infl ammatory bowel disease management clearly illustrates how genetic testing can positively aff ect patient care. It is the hope that as the understanding of science regarding the human genome grows, the clinical implications of our genetic variants will soon be uncovered and will signifi cantly change clinical practice and patient management of GI disorders in the 21st century. 
